A 61-year-old man is evaluated in the intensive care unit to optimize his medication regim… — USMLE Step 2 CK

A 61-year-old man is evaluated in the intensive care unit to optimize his medication regimen. He was admitted a week ago after sustaining multiple severe injuries in a high-speed motorcycle collision. He required immediate intubation and has remained mechanically ventilated. Three days ago, he developed a temperature of $39.0^\circ\text{C}$ ( $102.2^\circ\text{F}$ ), a heart rate of $112/\text{min}$ , thick purulent airway secretions, and a leukocytosis of $18,500/\mu\text{L}$ . A portable chest radiograph demonstrated a new dense consolidation in the right lower lobe. He was promptly started on a broad-spectrum empiric antimicrobial regimen consisting of intravenous vancomycin, cefepime, and tobramycin.

Today, his clinical trajectory has improved; his temperature is $37.2^\circ\text{C}$ ( $99.0^\circ\text{F}$ ), his heart rate is $85/\text{min}$ , and his fraction of inspired oxygen ( $\text{FiO}_2$ ) has been successfully titrated down. Blood cultures drawn three days ago show no growth. A quantitative culture of an endotracheal aspirate obtained at the onset of his fever grew $>10^5\text{ colony-forming units/mL}$ of *Pseudomonas aeruginosa*. The isolate's susceptibility profile is as follows:

Amikacin: Susceptible
Cefepime: Susceptible
Ciprofloxacin: Susceptible
Meropenem: Susceptible
Tobramycin: Susceptible

Routine morning laboratory results reveal a serum creatinine level of $2.2 \text{ mg/dL}$ , which has climbed from a baseline of $1.0 \text{ mg/dL}$ on admission.

Which of the following is the most appropriate next step in the management of this patient's infection?

Discontinue vancomycin and tobramycin, and continue cefepime.Answer
B
Discontinue vancomycin, and continue cefepime and tobramycin.
C
Discontinue tobramycin, and continue vancomycin and cefepime.
D
Discontinue vancomycin and tobramycin, and replace cefepime with meropenem.
E
Continue the current regimen of vancomycin, cefepime, and tobramycin.

Answer

Discontinue vancomycin and tobramycin, and continue cefepime.

The patient developed ventilator-associated pneumonia (VAP) and was initially given appropriate empiric therapy. Once culture data identifies a specific pathogen and its susceptibilities, antimicrobial stewardship principles dictate de-escalating to targeted, narrower-spectrum therapy. Since the cultures grew only *Pseudomonas aeruginosa*, MRSA coverage (vancomycin) is no longer indicated. Furthermore, for a patient with *P. aeruginosa* VAP who is clinically stabilizing, definitive treatment with a single active beta-lactam agent (in this case, cefepime) is recommended over combination therapy. Continuing the aminoglycoside (tobramycin) provides no additional clinical benefit and actively exacerbates the patient's ongoing acute kidney injury. Therefore, the best step is to stop vancomycin and tobramycin and complete the course with cefepime monotherapy.

Step-by-Step Solution

Analyze the patient's initial presentation and the rationale for empiric therapy.

The patient developed ventilator-associated pneumonia (VAP) and was appropriately started on broad-spectrum therapy (vancomycin, cefepime, tobramycin) to cover multidrug-resistant pathogens including MRSA and Pseudomonas.

Empiric therapy for severe healthcare-associated infections must account for local resistance patterns and potentially highly resistant organisms until cultures return.

Evaluate the definitive culture and susceptibility data against the patient's clinical status.

Cultures confirmed Pseudomonas aeruginosa sensitive to cefepime, with no MRSA isolated. The patient's clinical status is improving (afebrile, lower oxygen requirements).

Once the responsible pathogen and its susceptibility profile are identified, therapy should be tailored to target that specific organism.

Assess for adverse effects of the current medical regimen.

The patient's serum creatinine has more than doubled (1.0 to 2.2 mg/dL), indicating acute kidney injury (AKI).

Both vancomycin and tobramycin are nephrotoxic. Identifying AKI mandates urgent removal of offending agents if they are no longer clinically necessary.

Determine the optimal definitive antimicrobial regimen.

Discontinue both vancomycin (no MRSA) and tobramycin (nephrotoxic and unnecessary for double coverage), and continue cefepime monotherapy.

Current guidelines recommend monotherapy with a susceptible beta-lactam for stable patients with Pseudomonas VAP to promote antibiotic stewardship and limit toxicity.

Key Concept

Antimicrobial stewardship in ventilator-associated pneumonia requires de-escalating empiric broad-spectrum regimens to targeted monotherapy once susceptibilities are known and the patient is clinically stable, especially when avoiding drug toxicities like aminoglycoside-induced acute kidney injury.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic